Emerging biotech companies often face a critical commercialization decision: out-license an asset to gain immediate resources or retain ownership and pursue greater long-term value. This white paper explores the financial, operational and strategic implications of that decision, examining how commercialization models, capital constraints, launch readiness and risk management can influence enterprise value. Readers will gain practical insights to help evaluate commercialization pathways, preserve optionality and position assets for sustainable growth in today's increasingly complex market.
FDA grants accelerated approval to INOVIO’s Voceryq to reduce surgical burden in recurrent respiratory papillomatosis, Brox.AI’s Hamish Brocklebank on the three levels of digital clone use cases in pharma, and CytoDyn’s Dr. Jay Lalezari on his path from HIV clinician to CEO.
PhRMA's Scott LaGanga discusses the expanding influence of state policymaking on drug pricing, PBM reform, and efforts to translate policy changes into lower out-of-pocket costs for patients.
Brox.AI's co-founder and CEO on why telling an AI to pretend to be a doctor isn’t the same as cloning one — and why that distinction matters for pharma.
Earlier pediatric planning, innovative trial design, and closer collaboration among regulators, industry, and families are needed to close the persistent gap between the evidence available for adult and pediatric treatments.
